The United States of America v. Gilead Sciences, Inc. et al
Case Number:
1:19-cv-02103
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 21, 2025
DACA Health Coverage, Gilead IP Deal And PBM Insulin Case
Several state attorneys general are looking to defend immigrants' Affordable Care Act coverage, while a group of pharmacy benefit managers failed to oust the FTC's Democratic members from a case alleging collusion to inflate insulin prices. Law360 Healthcare Authority looks at the cases and decisions that shaped the industry over the last week.
-
January 15, 2025
Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal
Gilead Sciences and the federal government have agreed to dismiss all claims and counterclaims in a yearslong intellectual property and contract battle over HIV prevention drugs Truvada and Descovy, according to stipulations of voluntary dismissal filed Wednesday in both the Federal Circuit and Delaware federal court.
-
May 09, 2024
Judge Clarifies Gilead Didn't Directly Infringe HIV Drug IP
A Delaware federal judge on Thursday rejected Gilead Sciences' request to amend her judgment finding that two medications in its HIV prevention regimen, Truvada and Descovy, directly infringed the government's invalidated patents, but clarified her judgment to say that non-party patients or physicians committed the infringement.
-
May 02, 2024
Feds Call Out Gilead's Efforts To Revise HIV Drug IP Judgment
The U.S. Department of Justice has asked a Delaware federal judge to reject Gilead Sciences' motion to modify a judgment finding that two medications in its HIV prevention regimen directly infringe voided patents owned by the government, arguing that the pharmaceutical company's attempt to rewrite the judgment is "unnecessary as well as improper."
-
March 22, 2024
Gilead's Win Upheld In Billion-Dollar HIV Drug Patent Case
A Delaware federal judge on Friday largely upheld a jury's verdict rejecting the government's potentially billion-dollar claim that Gilead Sciences Inc. infringed patents covering HIV drugs, ruling that the jury was correct in finding Gilead didn't cause doctors and patients to infringe.
-
June 21, 2023
Feds Fight Gilead's Win In Billion-Dollar HIV Patent Trial
The U.S. government urged a Delaware federal judge Tuesday to overturn a jury's verdict invalidating three federal patents on HIV treatments and clearing drugmaker Gilead Sciences Inc. of claims it infringed the patents while racking up billions in sales.
-
June 01, 2023
Gov't Told To Keep Fighting 'Unexpected' HIV Patent Loss
The International Planned Parenthood Federation and more than 30 other organizations have thrown their support behind the U.S. government after a Delaware federal jury invalidated three federal patents on HIV treatments and cleared drugmaker Gilead of infringement claims, arguing that the government must "continue to press its case" through an appeal or other means.
-
May 09, 2023
Jury Rejects Feds' Claims Gilead Infringed HIV Drug Patents
A six-member federal jury in Delaware rejected a potential billion-dollar government claim Tuesday that Gilead Sciences Inc. infringed government-owned patents when it fielded its Truvada and Descovy drugs to treat or reduce the risk of HIV infections.
-
April 27, 2023
IP Forecast: Gov't To Face Off Against Gilead In Delaware
In one of its first-ever patent infringement cases against a private company, the federal government next week will argue before a Delaware jury that Gilead is making billions of dollars in sales from HIV treatments that allegedly violate government-owned patents. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.
-
April 04, 2023
Gilead, DOJ Allowed To Redact Remaining Docs In Patent Row
The federal government and Gilead Sciences Inc. got approval from a federal judge Tuesday to redact a limited number of documents after making public dozens of previously sealed filings in response to a third-party challenge, ahead of a May trial on their patent dispute over HIV drugs Truvada and Descovy.